Current status and future perspectives on alcohol septal ablation for hypertrophic obstructive cardiomyopathy

Rami Khouzam, Srihari S. Naidu

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease. Patients may present with a wide variety of symptoms, ranging from relatively asymptomatic to heart failure, recurrent syncope, angina, or sudden death. Once diagnosed, a thorough clinical, anatomic and physiologic assessment should be undertaken. Treatment options include both pharmacologic and invasive therapies, with a goal to reduce symptoms and possibly extend longevity. Traditionally, the "gold standard" for treating severe obstructive HCM has been ventricular septal myotomymyomectomy. Since its introduction in 1994, alcohol septal ablation (ASA) has emerged as an acceptable alternative in patients who meet strict anatomic criteria, and has been supported in recent guidelines. We review the indications, technique, competency requirements, alternatives, outcomes, complications, and future directions of ASA.

Original languageEnglish (US)
JournalCurrent Cardiology Reports
Volume16
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Hypertrophic Cardiomyopathy
Alcohols
Inborn Genetic Diseases
Syncope
Sudden Death
Heart Diseases
Heart Failure
Guidelines
Therapeutics
Direction compound

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Current status and future perspectives on alcohol septal ablation for hypertrophic obstructive cardiomyopathy. / Khouzam, Rami; Naidu, Srihari S.

In: Current Cardiology Reports, Vol. 16, No. 5, 01.01.2014.

Research output: Contribution to journalReview article

@article{f8bf1099e1154dda88f81b5ce1bc3a86,
title = "Current status and future perspectives on alcohol septal ablation for hypertrophic obstructive cardiomyopathy",
abstract = "Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease. Patients may present with a wide variety of symptoms, ranging from relatively asymptomatic to heart failure, recurrent syncope, angina, or sudden death. Once diagnosed, a thorough clinical, anatomic and physiologic assessment should be undertaken. Treatment options include both pharmacologic and invasive therapies, with a goal to reduce symptoms and possibly extend longevity. Traditionally, the {"}gold standard{"} for treating severe obstructive HCM has been ventricular septal myotomymyomectomy. Since its introduction in 1994, alcohol septal ablation (ASA) has emerged as an acceptable alternative in patients who meet strict anatomic criteria, and has been supported in recent guidelines. We review the indications, technique, competency requirements, alternatives, outcomes, complications, and future directions of ASA.",
author = "Rami Khouzam and Naidu, {Srihari S.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s11886-014-0478-3",
language = "English (US)",
volume = "16",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "5",

}

TY - JOUR

T1 - Current status and future perspectives on alcohol septal ablation for hypertrophic obstructive cardiomyopathy

AU - Khouzam, Rami

AU - Naidu, Srihari S.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease. Patients may present with a wide variety of symptoms, ranging from relatively asymptomatic to heart failure, recurrent syncope, angina, or sudden death. Once diagnosed, a thorough clinical, anatomic and physiologic assessment should be undertaken. Treatment options include both pharmacologic and invasive therapies, with a goal to reduce symptoms and possibly extend longevity. Traditionally, the "gold standard" for treating severe obstructive HCM has been ventricular septal myotomymyomectomy. Since its introduction in 1994, alcohol septal ablation (ASA) has emerged as an acceptable alternative in patients who meet strict anatomic criteria, and has been supported in recent guidelines. We review the indications, technique, competency requirements, alternatives, outcomes, complications, and future directions of ASA.

AB - Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease. Patients may present with a wide variety of symptoms, ranging from relatively asymptomatic to heart failure, recurrent syncope, angina, or sudden death. Once diagnosed, a thorough clinical, anatomic and physiologic assessment should be undertaken. Treatment options include both pharmacologic and invasive therapies, with a goal to reduce symptoms and possibly extend longevity. Traditionally, the "gold standard" for treating severe obstructive HCM has been ventricular septal myotomymyomectomy. Since its introduction in 1994, alcohol septal ablation (ASA) has emerged as an acceptable alternative in patients who meet strict anatomic criteria, and has been supported in recent guidelines. We review the indications, technique, competency requirements, alternatives, outcomes, complications, and future directions of ASA.

UR - http://www.scopus.com/inward/record.url?scp=84897464979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897464979&partnerID=8YFLogxK

U2 - 10.1007/s11886-014-0478-3

DO - 10.1007/s11886-014-0478-3

M3 - Review article

VL - 16

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 5

ER -